CCL5/RANTES Antibody (53405) [Alexa Fluor® 700]

• Reactivity: Mu
• Applications: B/N, ICC/IF
• Clone: 53405
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 700

CCL5/RANTES Antibody (53405) [Alexa Fluor® 700] Summary

• Immunogen: E. coli-derived recombinant mouse CCL5/RANTES
  Ser24-Ser91
  Accession # P30882
• Specificity: Detects mouse CCL5/RANTES in direct ELISAs. Shows 50% cross-reactivity with recombinant human (rh) CCL5, and no cross-reactivity with recombinant feline CCL5, rhCCL3, recombinant mouse (rm) CCL3, rmCCL4, rhCCL4, rhCCL14, or rhCCL18.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Neutralization

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL5/RANTES Antibody (53405) [Alexa Fluor® 700]

• CCL5
• chemokine (C-C motif) ligand 5
• D17S136Enormally T-expressed, and presumably secreted
• EoCP
• Eosinophil chemotactic cytokine
• RANTES
• SISd
• SIS-delta
• small inducible cytokine A5 (RANTES)
• small inducible cytokine subfamily A (Cys-Cys), member 5
• Small-inducible cytokine A5
• T cell-specific protein P228
• T-cell specific protein p288
• TCP228T-cell-specific protein RANTES

Background

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1-3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature mouse CCL5 shares 100% amino acid (aa) sequence identity with rat CCL5 and 75-88% with canine, cotton rat, feline, and human CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11-13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14-16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of pro-inflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.